Renaissance Technologies
ARTL icon

Renaissance Technologies’s Artelo Biosciences ARTL Stock Holding History

Renaissance Technologies’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-676
Closed -$82K – 4203
2022
Q1 		$82K Buy
676
+273
+68% +$31.4K ﹤0.01% 3826
2021
Q4 		$56K Sell
403
-644
-62% -$127K ﹤0.01% 3773
2021
Q3 		$223K Sell
1,047
-1,015
-49% -$258K ﹤0.01% 3168
2021
Q2 		$663K Buy
+2,062
New +$705K ﹤0.01% 2847

Other funds holding ARTL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

Renaissance Technologies's ARTL Position: Q2 2022 in Review

Renaissance Technologies sold out of Artelo Biosciences (ARTL) in Q2 2022, closing a stake of 676 shares — an estimated $82K sold.

Renaissance Technologies first reported a position in ARTL in Q2 2021 and held it in 4 quarters. The position peaked at $663K in Q2 2021. 15 funds tracked by Wall St. Rank hold ARTL as of Q2 2022.

  • Renaissance Technologies reported no remaining Artelo Biosciences position as of Q2 2022 after selling out during the quarter.
  • Renaissance Technologies sold 676 Artelo Biosciences shares in Q2 2022, an estimated $82K.
  • Renaissance Technologies first reported a position in Artelo Biosciences in Q2 2021 and held it in 4 quarters.
  • Renaissance Technologies's Artelo Biosciences position peaked at $663K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2022.

Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.